Neonatal Life Events and the Risk of Inflammatory Bowel Disease

João Sabino; Joana Torres; Jean Fréderic Colombel; Inga Peter

doi:10.1053/j.gastro.2019.04.055

Neonatal Life Events and the Risk of Inflammatory Bowel Disease

João Sabino, Joana Torres, Jean Fréderic Colombel, Inga Peter

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	1440-1441
Number of pages	2
Journal	Gastroenterology
Volume	157
Issue number	5
DOIs	https://doi.org/10.1053/j.gastro.2019.04.055
State	Published - Nov 2019

Access to Document

10.1053/j.gastro.2019.04.055

Cite this

@article{735b88e47883476aa07e707bb92912b4,

title = "Neonatal Life Events and the Risk of Inflammatory Bowel Disease",

author = "Jo{\~a}o Sabino and Joana Torres and Colombel, {Jean Fr{\'e}deric} and Inga Peter",

note = "Funding Information: Conflicts of interest The authors have made the following disclosures: JS has received speaker fees from Abbvie and Nestle Health Sciences. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag, and Theravance Biopharma; and holds stock options in Intestinal Biotech Development and Genfit. JT and IP have no conflicts of interest.",

year = "2019",

month = nov,

doi = "10.1053/j.gastro.2019.04.055",

language = "English",

volume = "157",

pages = "1440--1441",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - Neonatal Life Events and the Risk of Inflammatory Bowel Disease

AU - Sabino, João

AU - Torres, Joana

AU - Colombel, Jean Fréderic

AU - Peter, Inga

N1 - Funding Information: Conflicts of interest The authors have made the following disclosures: JS has received speaker fees from Abbvie and Nestle Health Sciences. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag, and Theravance Biopharma; and holds stock options in Intestinal Biotech Development and Genfit. JT and IP have no conflicts of interest.

PY - 2019/11

Y1 - 2019/11

UR - http://www.scopus.com/inward/record.url?scp=85073678773&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2019.04.055

DO - 10.1053/j.gastro.2019.04.055

M3 - Letter

C2 - 31442434

AN - SCOPUS:85073678773

SN - 0016-5085

VL - 157

SP - 1440

EP - 1441

JO - Gastroenterology

JF - Gastroenterology

IS - 5

ER -